Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19)

PHASE3CompletedINTERVENTIONAL
Enrollment

3,000

Participants

Timeline

Start Date

September 16, 2020

Primary Completion Date

December 13, 2021

Study Completion Date

December 13, 2021

Conditions
COVID-19 Virus Infection
Interventions
BIOLOGICAL

Inactivated SARS-CoV-2 vaccine (Vero cell)

Immunization schedule: 2-doses of investigational vaccine or placebo are inoculated to the deltoid muscle of the upper arm according to the immunization schedule of Day 0, 21.

BIOLOGICAL

Placebo/Aluminum Adjuvant of Inactivated SARS-CoV-2 vaccine

Immunization schedule: 2-doses of investigational vaccine or placebo are inoculated to the deltoid muscle of the upper arm according to the immunization schedule of Day 0, 21.

Trial Locations (4)

C1202ABB

Fundación Huésped, Ciudad Autónoma de Buenos Aires

C1408FVD

Vacunar Liniers, Ciudad Autónoma de Buenos Aires

C1426BOF

Vacunar Cañitas, Ciudad Autónoma de Buenos Aires

C1430BKB

Vacunar Coghlan, Ciudad Autónoma de Buenos Aires

Sponsors
All Listed Sponsors
collaborator

Beijing Institute of Biological Products Co Ltd.

INDUSTRY

collaborator

China National Biotec Group Company Limited

INDUSTRY

collaborator

Fundación Huésped

OTHER

lead

Laboratorio Elea Phoenix S.A.

INDUSTRY